DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

Thumbnail
View / Open Files
Authors
Kizhakeyil, Atish
Zaini, Nurmahirah Binte Mohammed
Poh, Zhi Sheng
Wong, Brandon Han Siang
Loh, Xinpeng
Ng, Aik Seng
Low, Zun Siong
Publication Date
2021-10-16
Journal Title
Molecular Cancer
Publisher
BioMed Central
Volume
20
Issue
1
Language
en
Type
Other
This Version
VoR
Metadata
Show full item record
Citation
Kizhakeyil, A., Zaini, N. B. M., Poh, Z. S., Wong, B. H. S., Loh, X., Ng, A. S., Low, Z. S., et al. (2021). DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes. [Other]. https://doi.org/10.1186/s12943-021-01437-0
Description
Funder: addenbrooke's charitable trust, cambridge university hospitals; doi: http://dx.doi.org/10.13039/501100002927
Keywords
Letter to the Editor, DDX3X mutation, Hematolymphoid malignancy, Prognosis, Tumour metastasis, Drug resistance
Sponsorship
nanyang technological university (L0412290)
ministry of education - singapore (MOE2017-T2-2-004)
national medical research council (OFLCG18May-0028, NMRC/TA/0051/2016)
kay kendall leukaemia fund (KKL649)
medical research council (MR/M008584/1)
wellcome trust (203151/Z/16/Z)
cancer research uk (A25117)
Identifiers
s12943-021-01437-0, 1437
External DOI: https://doi.org/10.1186/s12943-021-01437-0
This record's DOI: https://doi.org/10.17863/CAM.76994
Rights
Licence:
http://creativecommons.org/licenses/by/4.0/
Statistics


Total file downloads (since January 2020). For more information on metrics see the IRUS guide.